New JCVI advice on use of the AstraZeneca COVID-19 vaccine
The JCVI has issued new advice regarding the AstraZeneca COVID-19 vaccine after reports of extremely rare blood clots.
The Joint Committee on Vaccination and Immunisation (JCVI) has issued advice to the government on the use of the AstraZeneca coronavirus (COVID-19) vaccine, following reports of extremely rare blood clots in a very small number of people.
Professor Wei Shen Lim, COVID-19 Chair for JCVI, said:
Safety remains our number one priority. Based on the available data and evidence, JCVI has advised that it is preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AstraZeneca vaccine where available. This weighs up the risks of being seriously ill or dying from COVID-19 against the extremely small risk of a serious adverse event.
The COVID-19 vaccines have already saved thousands of lives and the benefit for the majority of the population is clear – if you are offered a vaccine, you should take it.
All those who have received a first dose of the AstraZeneca vaccine should continue to be offered a second dose of the same vaccine, irrespective of age.
UK Health Security Agency press office
10 South Colonnade
London
E14 4PU